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p32 heterozygosity protects against 
age- and diet-induced obesity by 
increasing energy expenditure
Yong Liu1,4, Patrick L. Leslie1,2, Aiwen Jin1, Koji Itahana1,5, Lee M. Graves3 & Yanping Zhang1,4
Obesity is increasing in prevalence and has become a global public health problem. The main cause of 
obesity is a perturbation in energy homeostasis, whereby energy intake exceeds energy expenditure. 
Although mitochondrial dysfunction has been linked to the deregulation of energy homeostasis, 
the precise mechanism is poorly understood. Here, we identify mitochondrial p32 (also known as 
C1QBP) as an important regulator of lipid homeostasis that regulates both aerobic and anaerobic 
energy metabolism. We show that while whole-body deletion of the p32 results in an embryonic 
lethal phenotype, mice heterozygous for p32 are resistant to age- and high-fat diet-induced ailments, 
including obesity, hyperglycemia, and hepatosteatosis. Notably, p32+/− mice are apparently healthy, 
demonstrate an increased lean-to-fat ratio, and show dramatically improved insulin sensitivity despite 
prolonged high-fat diet feeding. The p32+/− mice show increased oxygen consumption and heat 
production, indicating that they expend more energy. Our analysis revealed that haploinsufficiency 
for p32 impairs glucose oxidation, which results in a compensatory increase in fatty acid oxidation 
and glycolysis. These metabolic alterations increase both aerobic and anaerobic energy expenditure. 
Collectively, our data show that p32 plays a critical role in energy homeostasis and represents a 
potential novel target for the development of anti-obesity drugs.
Obesity has gained widespread recognition as a global pandemic caused by the over-nutrition and sedentary 
lifestyles that pervade most developed countries. From a public health perspective, central obesity is a major risk 
factor for metabolic disorders, including insulin resistance, hypertension, hyperlipidemia, non-alcoholic fatty 
liver disease, and cardiovascular disease1–4. Although the incidence of obesity is often attributed to unhealthy life-
style choices, studies have suggested that individual genetic susceptibility determinants play a significant role in 
predisposition towards obesity in response to over-nutrition5–7. Indeed, many genetic determinants contribute to 
energy homeostasis, which plays a central role in the storage and expenditure of calories consumed. At the cellu-
lar level, proper-functioning mitochondria are crucial for energy homeostasis, and deregulation of mitochondrial 
function has emerged as a major contributing factor to the development of metabolic disorders8, 9. Therefore, a 
better understanding of the molecular basis of the regulation of mitochondria in terms of aberrant fat accumula-
tion is crucial for understanding the pathophysiology of obesity and obesity-related metabolic disorders, as well 
as for the development of therapeutics to treat these diseases.
p32, also known as complement component 1-q subcomponent binding protein (C1QBP), was originally iso-
lated from the nucleus, where it binds to splicing factor-2 (SF2) and inhibits the binding of SF2 to pre-mRNA10, 11. 
Additional studies revealed that p32 is also expressed on the cell surface, where it binds to complement com-
ponent 1 (C1q) and mediates the immune response and inflammatory process12. Although p32 can be found in 
multiple cellular compartments, overwhelming evidence suggests that p32 predominantly resides in the mito-
chondria through its 33-residue N-terminal mitochondria-targeting signal (MTS) sequence13. Functional studies 
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have shown that down-regulation of p32 by shRNA results in the suppression of mitochondrial activity and a shift 
in glucose catabolism from oxidative phosphorylation (OXPHOS) towards glycolysis14.
To investigate the in vivo function of p32, we generated whole-body p32 knockout mice. Consistent with a 
previous study15, homozygous disruption of p32 causes early embryonic lethality. However, we unexpectedly 
discovered that p32 heterozygous mice, though developmentally normal, display robust resistance to both age- 
and high-fat diet-induced obesity and maintain insulin sensitivity well into late adulthood. Metabolic analyses 
revealed that p32+/− mice display higher levels of fatty acid oxidation and aerobic glycolysis, which results in 
increased energy expenditure and a leaner phenotype. Our study presents compelling evidence suggesting that 
p32 may be a suitable anti-obesity drug target for the development of inhibitors.
Results
Mice haploinsufficient for p32 are resistant to adulthood obese and diet-induced obesity. To 
investigate the in vivo function of p32, we generated p32 knockout mice by targeted deletion of p32 exon 3 
(Figure S1A). Consistent with a previous report15, homozygous deletion of p32 resulted in early embryonic lethal-
ity. However, p32 heterozygous deletion resulted in mice that are both developmentally normal and fertile, even 
though p32 protein expression was reduced by half (Figure S1B–D). Interestingly, when maintained on a normal 
chow diet ad libitum, p32+/− mice showed significantly reduced body weight gain starting at approximately 26 
weeks of age, whereas the WT littermates continued to gain weight (Fig. 1A). To further study the difference in 
body weight, we examined body composition of the mice in early (8 weeks) and late (52 weeks) adulthood by 
magnetic resonance imaging (MRI). At 8 weeks of age, p32+/− mice showed no differences in either body fat 
(Fig. 1B) or body lean (Fig. 1C) composition relative to WT mice. However, at 52 weeks of age, p32+/− mice dis-
played marked reduction in both total fat mass (Fig. 1B) and relative fat mass (Fig. 1C). In contrast, the 52-week-
old p32+/− mice showed normal amounts of total lean mass compared with their WT littermates (Fig. 1D), which 
corresponded to a significant increase in relative lean mass after normalization to total body weight (Fig. 1E).
Consistent with the MRI analysis, the epididymal fat pads isolated from 52-week old p32+/− mice weighed 
45% less than those of WT littermates (Fig. 1F). Histology analysis revealed smaller adipocytes in both epididy-
mal white adipose tissue (WAT) and interscapular brown adipose tissue (BAT) in the p32+/− mice (Fig. 1G), sug-
gesting that a reduction in size, but not number, of adipocytes is the underlying difference contributing to smaller 
fat depots and lower body fat content in p32+/− mice.
Because obesity profoundly affects how triglycerides (TG) are metabolized in the body, we compared serum TG 
levels between WT and p32+/− mice. Consistent with age-related obesity, serum TG levels in 52-week-old WT mice 
were significantly higher than those of 8-week-old WT mice. However, serum TG levels were essentially no differ-
ent between younger and older p32+/− mice, and the older p32+/− mice displayed serum TG levels similar to those 
observed in younger WT mice and significantly lower levels than those of older WT mice (Fig. 1H). To further 
investigate the differences in adiposity, we assessed fat accumulation in the mouse liver, an organ heavily involved 
in lipid metabolism. Livers from 52-week-old p32+/− mice exhibited remarkably reduced lipid droplet accumu-
lation compared with those from their WT littermates (Fig. 1I). Consistently, hepatic TG levels in 52-week-old 
p32+/− mice were approximately 60% lower than those of their WT littermates (Fig. 1J). Of note, although the 
actual size of the livers of 52-week-old p32+/− mice was smaller than those of the WT mice, the relative size of the 
p32+/− livers showed no difference from that of the WT mice after normalization to body weight (Fig. 1K).
To determine whether the decreased fat accumulation in p32+/− mice can be observed in a diet-induced obe-
sity model, we subjected 8-week-old WT and p32+/− mice to ad libitum high-fat diet (HFD) feeding. Similar 
to the results observed in the development of age-associated obesity, the p32+/− mice gained less body weight 
(Fig. 2A) and displayed lower levels of both total (Fig. 2B) and relative (Fig. 2C) body fat contents. Moreover, 
the p32+/− mice showed an unchanged total (Fig. 2D) and an increased relative (Fig. 2E) body lean composition 
compared with their WT littermates on an HFD. Collectively, these observations demonstrate that heterozygous 
deletion of p32 prevents lipid accumulation, which results in resistance to both adulthood obese and diet-induced 
obesity in mice.
Mice haploinsufficient for p32 demonstrate improved glucose tolerance and insulin sensitivity. 
Because obesity is associated with the development of insulin resistance, we tested p32+/− mice for their ability to 
regulate blood glucose levels. Consistent with reduced adiposity, we observed lower fasting blood glucose levels 
in 52-week-old p32+/− mice compared with their WT littermates (Fig. 3A). To directly assess insulin sensitivity, 
we subjected mice to a glucose tolerance test (GTT) and insulin tolerance test (ITT). Consistently, we found 
that the p32+/− mice display improved glucose tolerance (Fig. 3B) and enhanced insulin sensitivity (Fig. 3C) 
relative to WT mice. Similarly, HFD-fed p32+/− mice also displayed lower fasting blood glucose levels (Fig. 3D), 
improved glucose tolerance (Fig. 3E), and increased insulin sensitivity (Fig. 3F) relative to the HFD-fed WT mice. 
Based on these data, we conclude that p32 haploinsufficiency prevents age- and diet-induced obesity, as well as 
obesity-associated glucose intolerance and insulin resistance.
Mice haploinsufficient for p32 show increased caloric intake and energy expenditure. Obesity 
is often a result of increased caloric intake and/or impaired energy expenditure. To understand the underlying 
mechanism responsible for the resistance of p32+/− mice to fat gain, we examined the energy metabolism in 
52-week-old WT and p32+/− mice using a Comprehensive Lab Animal Monitoring System (CLAMS). When 
fed a normal chow diet ad libitum, despite reduced body weight gain, the p32+/− mice demonstrated increased 
caloric intake (Fig. 4A) compared with WT mice over a 24-h period and showed no difference in fecal lipid excre-
tion (Fig. 4B), suggesting that the p32+/− mice likely experience reduced efficiency in the utilization of energy. 
To test this possibility, we measured energy expenditure by indirect calorimetry using the CLAMS chamber. 
Consistent with our hypothesis, p32+/− mice exhibited increased energy expenditure (Fig. 4C) during both light 
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(day) and dark (night) phases compared with their WT controls (adjusted per kg of body weight), indicating that 
the p32+/− mice display an imbalance in energy uptake and consumption. Consistently, p32+/− mice fed an HFD 
also showed increased caloric intake (Fig. 4D) and energy expenditure (Fig. 4E). Collectively, these altered met-
abolic parameters in p32+/− mice indicate that their resistance to obesity occurs primarily as a result of increased 
energy expenditure due to sub-optimal energy production efficiency.
p32 haploinsufficiency results in decreased glucose oxidation and increased fatty acid oxidation. 
Because p32 is a mitochondrial protein13 and plays a role in mitochondrial metabolism14, we reasoned that 
p32 heterozygosity could have an impact on mitochondrial biology. We examined mitochondrial morphol-
ogy and total mitochondria mass and found no obvious differences in mitochondrial morphology (Fig. 5A) 
or total amount of mitochondrial mass, as measured by total mitochondrial DNA (Fig. 5B), between WT and 
p32+/− mouse embryonic fibroblast (MEF) cells. We then determined whether p32 heterozygosity might affect 
Figure 1. p32 heterozygosity confers resistance to age-associated obesity. (A) Body weights of male WT and 
p32+/− mice fed a normal chow diet (NC) (n = 8). (B–E) Fat mass (B), lean mass (D), and the percentages of 
body weight for fat (C) and lean mass (E) of 8-week-old and 52-week-old mice fed NC (n = 8). (F) Epididymal 
fat weight of 52-week-old mice fed NC (n = 4). (G) Representative hematoxylin and eosin (H and E) staining 
of WAT and BAT sections from 52-week-old mice fed NC. (H) Serum triglyceride levels of 8-week-old and 
52-week-old mice fed NC (n = 4). (I) Oil red O staining of liver sections from the 52-week-old mice fed NC. 
(J) Hepatic triglyceride levels of 52-week-old mice fed NC (WT n = 5; p32+/− n = 4). (K) Average liver mass of 
52-week-old mice fed NC (n = 4).
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mitochondrial function in the oxidation of glucose and fatty acids using a Seahorse XF24 analyzer. To measure 
basal oxidative capacity, oligomycin was injected into the culture wells prior to injection of the uncoupling agent 
carbonyl cyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP). When the cells were incubated with medium 
containing glucose, p32+/− MEFs showed decreased basal and maximal oxygen consumption rates (OCRs) 
(Fig. 5C). The maximal oxidative capacity, which is indicated by FCCP-sensitive OCR, was decreased by 40%. In 
compensation for the reduced energy production via oxidative phosphorylation, we found that glucose utilization 
in p32+/− MEFs was shunted to aerobic glycolysis, which was indicated by an increased extracellular acidification 
rate (ECAR) (Fig. 5D). To confirm the effect of p32 heterozygosity on glycolysis, we used 2-deoxyglucose (2-DG), 
a glucose analog, to inhibit hexokinase, which is the first enzyme in the glycolytic pathway that converts glucose 
to glucose-6-phosphate. The difference in ECAR between p32+/− and WT MEFs was abolished in the presence 
of 2-DG (Fig. 5D), supporting the notion that p32 heterozygosity enhances glycolysis. We also measured the 
plasma concentrations of lactate in p32+/− mice. Consistent with the observation of higher glycolytic flux in p32 
heterozygous MEFs, serum lactate levels in the p32+/− mice were increased by more than two-fold compared with 
WT mice (Fig. 5E).
Next, we tested mitochondrial activity with respect to the oxidation of fatty acids, the main alternative fuel 
source in animals under normal feeding conditions. Interestingly, despite reduced glucose oxidation, p32+/− 
MEFs showed increased OCR when cultured in medium containing BSA-conjugated palmitic acid (Fig. 5F), sug-
gesting that they are predisposed to higher levels of fatty acid oxidation (FAO) for the production of ATP. Indeed, 
p32 heterozygosity resulted in increased ATP production relative to WT cells (Fig. 5G). These data suggest that 
p32 haploinsufficiency causes an imbalance in mitochondrial metabolism, which results in a reduction in glucose 
oxidation that is compensated for by increased FAO.
Discussion
To elucidate the physiological functions of p32, we generated and studied p32 knockout mice. Interestingly, het-
erozygous p32 deletion in mice results in remarkable resistance to age-related and diet-induced illnesses such 
as obesity, hepatosteatosis, and insulin resistance. Obesity in mice, both age-related and diet-induced, occurs 
when acetyl-CoA production exceeds acetyl-CoA consumption through mitochondrial OXPHOS, leading to 
elevated lipogenesis and increased body fat deposition. The p32+/− mice showed reduced glucose oxidation, pos-
sibly because of the suppression of the function of mitochondrial complex I14, 15, and compensatory increases in 
glycolysis and FAO to make up for reduced ATP production due to the attenuation of OXPHOS. We postulate that 
reduced p32 levels results in alterations in mitochondrial metabolism and enhances both aerobic and anaerobic 
energy expenditure, which increases energy consumption and ameliorates adulthood obese and diet-induced 
obesity in the p32+/− mice (Fig. 6).
Mitochondria are central organelles for energy metabolism, as they link the Krebs cycle, which occurs in 
the mitochondrial matrix, to the electron transport chain (ETC), which is present in the inner mitochondrial 
membrane. In our study, p32 heterozygosity resulted in increased FAO and decreased glucose oxidation, two 
processes that rely on the ETC-OXPHOS machinery for energy production. Moreover, down-regulation of p32 by 
Figure 2. p32 heterozygous mice are resistant to HFD-induced obesity. (A) Body weight of 8-week-old WT and 
p32+/− male mice fed a high-fat diet (HFD) for the indicated amount of time (WT n = 7; p32+/− n = 5). (B–E) 
Average total fat (B) and lean (D) masses and relative fat (C) and lean (E) masses of WT and p32+/− mice fed an 
HFD for 10 weeks (WT, n = 7; p32+/−, n = 5).
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shRNA or disruption of the p32 gene results in the down-regulation of mitochondrial complex I, while complex 
II remains active and at normal levels14, 15. Thus, inactivation of complex I activity by p32 ablation largely blocks 
electron transfer from NADH to the downstream ETC components, which prevents the complete oxidation of 
glucose (Fig. 5C). Moreover, because glucose-derived succinate also becomes depleted in the absence of glucose 
oxidation, FADH2 derived from FAO becomes the only available electron donor for ETC-OXPHOS production 
when the p32 gene is disrupted. Thus, it is plausible that FAO is up-regulated to generate FADH2, which delivers 
electrons directly to complex II and thereby bypasses complex I, to meet cellular demands with respect to ATP 
production, which consequently results in increased aerobic energy expenditure in p32+/− mice (Fig. 4). Similar 
metabolic signatures and obesity-resistant phenotypes have also been observed in mouse models in which other 
critical mitochondrial function-related genes, such as AIF16, TFAM17 and Cox6a218, have been disrupted. These 
observations suggest that the mitochondria, as the energy plant of the cell, are important to maintain the exquisite 
balance between glucose and lipid metabolism and thus to control lipid storage.
It is intriguing that the p32+/− mice show a significant increase in food consumption but only a 20% increase in 
the oxygen consumption (VO2), suggesting that energy expenditure may be underestimated in the leaner p32+/− 
mice. Oxygen consumption estimates metabolic heat production and is commonly used to represent energy 
Figure 3. p32 heterozygosity increases glucose tolerance and insulin sensitivity. (A) Average fasting blood 
glucose levels of 52-week-old mice fed NC (n = 6). (B) Glucose tolerance test (GTT) and (C) insulin tolerance 
test (ITT) in 52-week-old mice fed NC (n = 6). Bar graphs to the right quantify the areas under the curves 
(AUC). (D) Average fasting blood glucose levels in mice fed an HFD for 10 weeks (WT, n = 7; p32+/−, n = 5). 
GTT (E) and ITT (F) assays in mice fed an HFD for 10 weeks (n = 5). Bar graphs to the right quantify the areas 
under the curves (AUC).
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expenditure. However, oxygen consumption measurements are not always proportional to energy expenditure. 
For example, when the contribution of anaerobic glycolysis to ATP production is large19, such as in patients with 
cancer-related cachexia20 or athletes performing intense exercise21, pyruvate is rapidly converted to lactate, anaer-
obic heat is released, and the VO2 no longer reflects total energy expenditure levels. In the case of p32+/− mice, 
glucose is predominantly metabolized through glycolysis, and a large amount of lactate is produced in p32+/− 
mice (Fig. 5D,E), suggesting that the actual energy expenditure is much higher when considering the combined 
energy expenditure contributions from both oxygen consumption and anaerobic heat release. Likewise, under 
conditions of metabolic acidosis (Fig. 5D,E), the respiratory exchange ratio (RER), calculated by VCO2/VO2, is an 
overestimation and is no longer appropriate to indicate the fuel source of catabolism because the organism tends 
to acquire ATP through glycolysis, which inflates the RER in a biased manner. Indeed, we observed a significantly 
higher RER in p32+/− mice compared with their wild-type littermates (Figure S2). Furthermore, accumulated 
lactate is reconverted to glucose and pyruvate by gluconeogenesis-competent cells in the liver, which requires fur-
ther consumption of ATP and likely constitutes a futile cycle. This additional use of ATP to recycle lactate likely 
contributes to the inefficient utilization of energy in p32+/− mice. Taken together, the underestimated energy 
expenditure and futile metabolic cycles additively contribute to the leaner phenotype in p32+/− mice.
Most interestingly, the leaner but otherwise normal phenotype of p32+/− mice offers a potential drug target 
that can be exploited therapeutically in anti-obesity efforts. The striking difference in fat accumulation in p32+/− 
mice with no apparent health deficiencies illustrates the potential of p32 as an anti-obesity target. Moreover, 
a recent drug screen yielded several compounds that bind to p32 with low-micromolar affinity22. Taking into 
account the reduced fat accumulation with the loss of only one copy of p32, even very low-affinity p32 inhibitors 
could be effective for the prevention of fat accumulation over the long term. Additionally, because the crystal 
structure of p32 has been reported23, rational drug design and optimization are realistic options. Future studies 
analyzing the effect of various p32 inhibitors on the health and fat accumulation in animal models could offer 
valuable data and promising drug candidates for anti-obesity clinical trials.
In conclusion, while a multitude of in vitro studies have identified potential functions of p32, using a p32 hete-
rozygous knockout mouse model, we offer the first physiological insight into the function of p32 in the regulation 
of energy homeostasis. We show that the deletion of a single allele of p32 is sufficient to produce resistance to obe-
sity and prolong the sensitivity of mice to insulin. This newly discovered obesity-resistant phenotype conveyed by 
p32 heterozygosity offers an intriguing therapeutic target in the fight against obesity that warrants further study.
Methods
Mice and cell culture. To generate p32+/− mice, a 7.5-kb mouse p32 gene-containing fragment was sub-
cloned into the pBluescript II SK vector and was used to create a p32 loxP targeting vector. This vector was 
Figure 4. p32+/− mice demonstrate increased caloric intake and energy expenditure. (A) Caloric intake in 
52-week-old mice fed NC (n = 5). Caloric intake is normalized to body weight. (B) Fecal lipid excretion in 
52-week-old mice fed NC (n = 5). (C) Heat release in 52-week-old mice fed NC (n = 3). (D) Caloric intake in 
mice fed an HFD (WT, n = 7; p32+/−, n = 5). Caloric intake is normalized to body weight. (E) Heat release in 
WT and p32+/− mice fed an HFD for ten weeks (n = 3). Statistical comparisons were evaluated by two-way-
ANOVA for the indirect calorimetry assay.
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Figure 5. p32 heterozygosity decreases glucose oxidation and increases glycolysis and FAO. (A) Representative 
image of the mitochondria in WT and p32+/− MEFs by Mito-Green staining. (B) Relative mtDNA amounts 
in WT and p32+/− MEFs determined by mtDNA/nuclear DNA ratio using qPCR. mtDNA: mCO1; nDNA: 
NDUFC1. (C) Basal oxygen consumption (basal OCR) and maximum mitochondrial respiration capacity 
(Maxi OCR, indicated by OCR in the presence of FCCP) in the presence of 25 mM glucose in WT and p32+/− 
MEFs determined using a Seahorse XF24 analyzer. Left, representative curve; Right, quantification of three 
independent experiments. (D) ECAR in WT and p32+/− MEFs determined using a Seahorse XF24 analyzer. 
ECAR upon glucose injection (indicated by Glc) minus that of 2DG injection represents the basal ECAR; ECAR 
with oligomycin injection (indicated by Oligo) minus that with 2DG injection represents maximum glycolytic 
flux. Left panel, representative curve; Right panel, quantification of three independent experiments. (E) Serum 
lactate levels of 52-week-old mice fed NC (n = 4). (F) Basal oxygen consumption (basal OCR) and maximum 
mitochondrial respiration capacity (Maxi OCR, indicated by OCR in the presence of FCCP) in the presence of 
150 μM palmitate in WT and p32+/− MEFs determined using a Seahorse XF24 analyzer. ETO (50 μM) was used 
as a system control. OCR without ETO minus that with ETO indicated the FAO-specific OCR. (G) Intracellular 
ATP levels in WT and p32+/− MEFs.
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constructed by inserting an FRT-PGK-Neo-FRT-loxP cassette into intron 2 and another loxP site into intron 3, 
followed by a PGK-Diphtheria toxin A (DTA) expression cassette at the 3′ end of the construct to be used as a 
negative selection marker (Figure S1A). WT and p32+/− mice on C57BL/6 backgrounds were bred and main-
tained in standard cages on a 12:12 h light/dark cycle with free access to normal chow (NC) or a high-fat diet 
(HFD, Research Diets) containing 60% fat. All mice were handled in strict accordance with our animal protocol 
(12–328), which was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of 
North Carolina Animal Care Facility. Mice used for HFD experiments were fed with NC until eight weeks of age, 
after which they were fed with an HFD for another ten weeks. Mouse embryonic fibroblasts (MEFs) were isolated 
from embryos at embryonic day (E) 13.5 and were cultured in DMEM medium supplemented with 10% FBS, 
penicillin (100 IU/ml), and streptomycin (100 µg/ml) in a 37 °C incubator with 5% CO2 and 3% O2.
Metabolic analyses. Body weights were recorded weekly. Body composition was assessed using an 
EchoMRI-100 quantitative magnetic resonance whole body composition analyzer (Echo Medical Systems). To 
determine energy intake, mice were housed individually for one week to allow for environmental habituation, 
after which food consumption was determined by weight every 24 hours for seven consecutive days. Energy intake 
in calories was calculated by multiplying the number of grams of normal chow diet or HFD consumed daily by 
3.93 kcal/gram or 5.49 kcal/gram, respectively. For metabolic studies, mice were placed individually in metabolic 
chambers of an Oxymax system (Columbus Instruments) and were allowed to acclimate during a 24-hour period. 
Then, readings were taken for five days. Water and food consumption data as well as energy expenditure were 
obtained and were normalized to body weight. For glucose tolerance tests, 16-hour-fasted mice were injected 
intraperitoneally with D-glucose (2.5 g/kg body weight). For insulin tolerance tests, 6-hour-fasted mice were 
injected with insulin (0.75 U/kg). Blood glucose concentrations were determined from tail vein blood samples 
collected at the designated time points and were measured using an ACCU-CHEK Aviva glucometer (Roche, 
Basel, Switzerland). Serum TG (Stanbio, Boerne, TX) and lactate (Biovision Inc., Milpitas, CA) levels were meas-
ured using colorimetric kits based on the protocol recommended by the manufacturer. For the hepatic TG meas-
urement, we used a modified protocol that was previously described by Ferraz24. Briefly, snap-frozen liver samples 
(30–50 mg) were homogenized using a motorized chuck and Teflon pestle in 1% Triton-x-100 in PBS at a con-
centration of 1 mg/dL. Samples were centrifuged for 1 min at 1500 × g, and the supernatant, including the fatty 
layer, was transferred to a fresh microcentrifuge tube. Supernatants were assayed for triglyceride content using the 
StanBio Triglyceride Liquicolor kit using the manufacturer’s recommended protocol (cat. no. 2100–430).
Oxygen consumption and glycolytic analysis. The oxygen consumption rate (OCR) and the extracellu-
lar acidification rate (ECAR) were evaluated using a Seahorse XF24 Analyzer (Seahorse Bioscience) as described 
previously25. Briefly, 6 × 104 MEF cells were seeded in each well of an XF24 cell plate 24 h before the assay. The 
basal levels of OCR (for the purpose of glucose oxidation) and ECAR were measured in XF assay medium con-
taining 4.5 g/L glucose followed by the addition of oligomycin (1 μM), which allows for the assessment of the 
maximal glycolytic capacity (ECAR), or by the sequential addition of oligomycin (1 μM), FCCP (0.5 μM) (max-
imal OXPHOS), and antimycin A (2 μM) plus rotenone (1 µM) to measure the OCR. For FAO measurement, 
6 × 104 MEF cells were seeded 24 h before the assay. FAO was measured by sequential injection of BSA-conjugated 
palmitate (150 μM), oligomycin (1 μM), FCCP (0.5 μM), and etomoxir (ETO, an irreversible inhibitor of carnitine 
palmitoyltransferase-1, 50 μM) in KHB (Krebs-Henseleit) buffer.
Histology. Epididymal fat pad and interscapular brown adipose tissue samples were fixed and 
paraffin-embedded. Tissue sections were subjected to standard hematoxylin and eosin staining. For oil red O 
staining, mouse liver tissues were fixed in 10% neutral formalin for 24 h and then were submerged in 20% sucrose 
for 2 days. The liver pieces were then frozen in optimal cutting temperature (OCT) solution, and 5-µm-thick tis-
sue sections were cut. Oil red O staining was conducted according to the standard protocol used in the Histology 
Research Core Facility at the University of North Carolina at Chapel Hill.
Figure 6. p32 heterozygosity confers resistance to obesity by remodeling glucose and lipid metabolism.
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Western blotting. Procedures and conditions for immunoblotting were previously described26. Briefly, 
mouse tissues were homogenized and lysed in tissue lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM 
EDTA, 2 mM EGTA, 0.2% Triton X-100, 0.3% NP-40, and protease inhibitor cocktail). Goat polyclonal anti-p32 
(sc-10258, Santa Cruz, Dallas, TX) antibody was purchased commercially.
Statistical analysis. Data were analyzed using Graph Pad Prism 5.0 software (La Jolla, CA). Statistical 
comparisons were evaluated using an unpaired Student’s t-test if not otherwise specified. P-values < 0.05 were 
considered statistically significant (*, **, and *** are used to indicate statistical significance corresponding to 
p-values < 0.05, 0.01, and 0.001, respectively). All results are presented as the means ± standard deviation.
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